Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
August 26, 2023
0
Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product has been game changer in the treatment of various difficult to treat cancers before the products that target PD-L1 and approved for several various cancers were developed by MRK and BMY. Exelixis (EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data . . . …